Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
Background Efforts to modulate the function of tumor-associated myeloid cell are underway to overcome the challenges in immunotherapy and find a cure. One potential therapeutic target is integrin CD11b, which can be used to modulate the myeloid-derived cells and induce tumor-reactive T-cell response...
Saved in:
Main Authors: | Mei Zhang, Veronique Roche, Victor Sandoval, Claire Wolford, Zachary Senders, Julian Anthony Kim, Susan Pereira Ribeiro, Alex Yicheng Huang, Rafick-Pierre Sekaly, Joshua Lyons |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/6/e006205.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy
by: Saskia Stier, et al.
Published: (2013-01-01) -
Natural killer cell engagers for cancer immunotherapy
by: Shahryar Khoshtinat Nikkhoi, et al.
Published: (2025-01-01) -
Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01) -
Carbohydrate intolerance
by: V. O. Kaybysheva, et al.
Published: (2018-08-01) -
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01)